Each year the American Medical Association’s CPT code manual is revised to delete codes and/or guidelines, and to add or revise codes to reflect current technologies, techniques and services. Medicare and all other payers are switching to the new 2018 CPT codes for X-rays of the chest. The original codes for a chest X-ray were…
Search results for: biosimilar
Year in Review: The ACR/ARHP/RheumPAC’s Advocacy Efforts in 2017
In 2017, did you interact with the Medicare payment system, receive payment for a consultation code or worry about the Centers for Medicare & Medicaid Services (CMS) reducing reimbursement through its proposed Part B Demonstration Project? If your answer to any of those questions is yes, then you directly benefited from the ACR/ARHP’s advocacy efforts….
Rheumatologists from Minnesota Team with Dakotas’ Colleagues to Form State Society
Generating articles of incorporation, convening boards of directors, establishing nonprofit status: It’s no small feat to form a state rheumatology society, but with the right expertise, the results can be successful, according to the president of the Rheumatology Association of Minnesota and the Dakotas, Jody Hargrove, MD, who is in private practice with Arthritis &…
ACR Advocacy: Past Wins, Future Outlook
Greetings, advocates! Your government is back to work after ending a brief government shutdown by passing a short-term continuing resolution (CR), which will keep the government running at current funding levels into February. At some point, it would be great for Congress to pass a budget (instead of a CR) and to enact bipartisan plans…
The ACR’s 2018 Legislative & Regulatory Priorities
A recent Politico article outlined the looming agenda facing Congress as 2018 begins: Fund the government, raise the debt ceiling, modify spending caps, address healthcare subsidies, allocate additional funds for disaster relief, and address the status of millions of undocumented young immigrants.1 Amid all that activity, the ACR, through its Government Affairs Committee (GAC) and…
Meet Chris Adams, MD, the New Chair of the ACR’s Affiliate Society Council
What initially strikes people about Christopher Adams, MD, FACP, FACR, is his passion for fairness. In 2015, he told readers of The Rheumatologist, “Patients often feel powerless to fight the system and advocate for themselves, and many of my patients felt they lacked a mechanism for addressing their concerns. That’s where we come in.” Dr….
Sen. Lisa Murkowski Addresses Rheumatologists During ACR/ARHP Annual Meeting, Tax Reform & More
Greetings, advocates! This month’s Washington update covers how Congress’s tax proposals affect rheumatology, the ACR’s plan to fight Medicare’s adjustments to Part B drug costs in MIPS, the good news of Medicare’s new individualized biosimilar reimbursement, advances in the rheumatology-specific Alternative Payment Model and developments in Congress’s awareness about the perilous pharmacy benefit manager system….
Trump Administration Proposes Medicare Rules Aimed at Opioids, Drug Costs
(Reuters)—The Trump administration on Thursday proposed changes to Medicare drug plans including limits on opioid prescriptions and rules aimed at reducing drug costs for seniors, such as requiring health insurers to pass on discounts to consumers. To help combat overprescription and abuse of addictive painkillers, the U.S. Centers for Medicare and Medicaid Services (CMS) said…
Year in Review: The ACR Advances Education, Rheumatic Disease Awareness, Strategic Planning in 2017
It seems like yesterday I was asked to write my first presidential column, and here I am penning my last. It’s incredible how fast the time goes and yet how much gets done. That progress is made possible by the dedicated and talented group of ACR volunteers and staff. This year, the College has had…
Novartis to Shut U.S. Generics Plant, Cut 450 Jobs
ZURICH (Reuters)—Swiss drugmaker Novartis is to cut 450 jobs in the United States over the next two years as it gradually shuts a generics manufacturing plant in Colorado and discontinues some products in the face of intense price pressures. “To remain competitive in the U.S., Novartis will discontinue or divest limited growth products in saturated…
- « Previous Page
- 1
- …
- 28
- 29
- 30
- 31
- 32
- …
- 42
- Next Page »